These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6099688)

  • 21. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation.
    Uhl GR; Hackney GO; Torchia M; Stranov V; Tourtellotte WW; Whitehouse PJ; Tran V; Strittmatter S
    Ann Neurol; 1986 Aug; 20(2):194-203. PubMed ID: 3019228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
    Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The life history of brain dopamine].
    Hornykiewicz O
    Wien Klin Wochenschr; 1985 Apr; 97(8):350-4. PubMed ID: 2986364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synaptic and non-synaptic striatal dopamine D2 receptors: possible implications in normal and pathological behaviour.
    Korf J; Loopuijt LD
    Acta Morphol Neerl Scand; 1988-1989; 26(2-3):177-90. PubMed ID: 2908162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K
    Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
    Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
    Zeevalk GD; Manzino L; Sonsalla PK
    Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
    Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
    J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
    Abramsky O; Litvin Y
    Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D-1 receptors in the parkinsonian brain.
    Rinne JO; Rinne JK; Laakso K; Lönnberg P; Rinne UK
    Brain Res; 1985 Dec; 359(1-2):306-10. PubMed ID: 2934111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Parkinson's disease: problems with a progressing disease.
    Rinne UK
    J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.